Fig. 1 · Structure

Documents & Downloads

Aripiprazole

Cat. No. A11801 CAS 129722-12-9

5-HT1A receptor agonist

Aripiprazole is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.

In Stock

Publications for Aripiprazole

1 publication citing this product

  1. Jaime Osuna-Luque, .et al. , J Exp Neurosci, 2018, 12: 1179069518798628 PMID: 30245571

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Aripiprazole shows assay-dependent D2 receptor activity. In HEK-D2/AC5 cells it partially inhibited forskolin-stimulated cAMP accumulation (EC50 4.1 nM; maximal effect 48 ± 9% of dopamine’s response). In the D2/AC2 reporter it showed no detectable agonist response and blocked dopamine-driven signaling (IC50 2.8 nM). These results support partial agonism with pathway-dependent activity; they do not establish a universal intrinsic efficacy. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
5-HT1A Ki 4.2 nM

Cellular Effect

Cell Line Activity Value Description Reference
CHO IC50 7.6 nM Antagonist activity at human D2 dopamine receptor expressed in CHO cell membrane by GTPgammaS-binding assay [PMID: 23237836]
HEK293 IC50 > 100 μM Cytotoxicity against HEK293 cells measured after 24 hrs by MTT assay [PMID: 35176563]
HEK293 EC50 > 5 μM Agonist activity at human dopamine D2 receptor expressed in HEK293 cells assessed as cAMP inhibition by BRET assay [PMID: 28300398]
HEK293 EC50 > 5 μM Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay [PMID: 28300398]
HEK293 EC50 > 5 μM Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay [PMID: 28300398]
HEK293 EC50 > 5 μM Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay [PMID: 28300398]
HEK293 IC50 > 500 μM Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 11 nM Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay [PMID: 24831693]
HEK293 IC50 130 μM Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
HEK293 EC50 160 nM Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphai2 after 30 mins by [35S]GTPgammaS binding assay [PMID: 24831693]
HEK293 EC50 20 nM Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay [PMID: 24831693]
HEK293 IC50 239 μM Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay [PMID: 23241029]
HEK-293T EC50 1 nM Agonist activity at human D2L receptor expressed in HEK293T cells coexpressing Gi subunit assessed as inhibition of isoproterenol-stimulated cAMP production by luminescence assay [PMID: 22845053]
HEK-293T EC50 1100 nM Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay [PMID: 28489379]
HEK-293T EC50 130 nM Agonist activity at human D2S receptor expressed in HEK293T cell membranes coexpressing Galphao1 assessed as induction of nucleotide exchange preincubated for 30 mins followed by addition of [35S]GTPgammaS measured after 30 mins by [35S]GTPgammaS binding [PMID: 28489379]
HEK-293T EC50 160 nM Agonist activity at human Dopamine D2S receptor expressed in HEK293T cell membranes coexpressing Galphai2 incubated for 30 mins measured after 75 mins by [35S]GTPgammaS binding assay [PMID: 28248104]
HEK-293T EC50 20 nM Agonist activity at human Dopamine D3 receptor expressed in HEK293T cell membranes coexpressing GalphaoA incubated for 30 mins measured after 75 mins by [35S]GTPgammaS binding assay [PMID: 28248104]
HEK-293T EC50 39 nM Agonist activity at human Dopamine D2S receptor expressed in HEK293T cell membranes coexpressing GalphaoA incubated for 30 mins measured after 75 mins by [35S]GTPgammaS binding assay [PMID: 28248104]

18 records · Scroll to view more

In Vitro Studies

The D2/AC5 agonist EC50 was 4.1 nM (95% CI 0.6–30 nM). In the separate D2/AC2 antagonist assay, aripiprazole fully inhibited the response to 300 nM dopamine, with IC50 2.8 nM (95% CI 1.3–5.9 nM). These fitted assay potencies are distinct from fixed treatment concentrations and receptor-binding affinities. [1]

Partial agonism in the D2/AC5 cAMP assay

Cell-based study · HEK cells stably expressing long-form dopamine D2 receptor and adenylyl cyclase 5 (HEK-AC5/D2). [1]

Aripiprazole partially inhibited forskolin-stimulated cAMP accumulation. Its maximal effect was 48 ± 9% of dopamine’s response; potency and efficacy are specific to this cellular reporter system.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of forskolin-stimulated cAMP accumulationEC50 4.1 nM (95% CI 0.6–30 nM)[1]
Maximal inhibition relative to dopamine responseMaximal effect 48 (±9)% of dopamine response (standard error)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response experiment; EC50 is a fitted endpoint, not a fixed treatment concentration.
Exposure duration
1 h at room temperature during cAMP accumulation.
Method
cAMP assay with 3 µM forskolin and 0.5 mM IBMX; dopamine and quinpirole reference agonists.
Reported limits
Assay drug vehicle and exact replicate count beyond at least three independent experiments in duplicate were not reported in the read methods. Nominal dose series not transcribed.
Methods and source locations

Compound reported in the paper: Aripiprazole

Evidence applies to the reported research material; no salt conversion, current Adooq lot equivalence, or clinical efficacy inferred.

Methods 2.1–2.3, 2.7; Results 3.1; Figure 1 and Table 1 (Gαi/o columns)

Inhibition of forskolin-stimulated cAMP accumulation: cAMP quantified with Cisbio dynamic 2 assay; at least three independent experiments conducted in duplicate. — Table 1, aripiprazole row, Gαi/o EC50; Methods 2.3 and 2.7

Maximal inhibition relative to dopamine response: Table 1 reports standard errors; dopamine reference maximum 100 (±3)%. — Table 1, aripiprazole and dopamine rows, Gαi/o Max; Figure 1

Dopamine antagonism without agonist activity in the D2/AC2 reporter

Cell-based study · HEK cells stably expressing long-form dopamine D2 receptor and adenylyl cyclase 2 (HEK-AC2/D2). [1]

Aripiprazole did not enhance PMA-stimulated AC2 activity when tested alone. In antagonist mode it fully inhibited the dopamine response, with IC50 2.8 nM. AC2 potentiation is an indirect reporter of Gβγ signaling.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of dopamine-driven potentiation of PMA-stimulated cAMP accumulationIC50 2.8 nM (95% CI 1.3–5.9 nM)[1]
Aripiprazole alone in the Gβγ/AC2 reporterAgonist response No enhancement detected; EC50 ND[1]

Literature-Reported Treatment Conditions

Treatment concentration
Aripiprazole concentration-response; antagonist mode used 300 nM dopamine.
Exposure duration
Antagonist pretreatment 30 min, then 1 h cAMP accumulation. Agonist-mode accumulation 1 h.
Method
cAMP assay with 1 µM PMA and 0.5 mM IBMX; dopamine/quinpirole agonist controls, haloperidol/clozapine antagonist comparators.
Co-treatment
Antagonist-mode effect is aripiprazole added before dopamine; agonist-mode test is aripiprazole alone.
Reported limits
Drug vehicle and exact nominal concentration series not transcribed; Gβγ agonist EC50 was ND for aripiprazole, not zero.
Methods and source locations

Compound reported in the paper: Aripiprazole

Evidence applies to the reported research material; no salt conversion, current Adooq lot equivalence, or clinical efficacy inferred.

Methods 2.1–2.2, 2.4, 2.7; Results 3.2; Figure 2A–B and Table 1 (Gβγ columns)

Inhibition of dopamine-driven potentiation of PMA-stimulated cAMP accumulation: At least three independent experiments conducted in duplicate; Results 3.2 supplies fitted value, Figure 2B supplies design. — Results 3.2, antagonist paragraph; Figure 2B caption; Methods 2.7

Aripiprazole alone in the Gβγ/AC2 reporter: Dopamine and quinpirole enhanced PMA-stimulated cAMP; aripiprazole did not. — Results 3.2; Figure 2A; Table 1 aripiprazole Gβγ EC50 ND / Max dash

In Vivo Studies

In live C. elegans, 300 µM aripiprazole reduced gentle-touch responses in wild-type N2 animals. The drug-associated difference was not significant in dop-1 or dop-2 single mutants but remained significant in dop-3 mutants. This behavioral evidence suggests receptor involvement without demonstrating direct binding or mammalian efficacy. [2]

Acute oral aripiprazole (3 or 10 mg/kg) reduced VTA dopamine-neuron population activity in MAM-model rats, with no significant reduction in saline-model controls. A separate sequential-treatment experiment found the opposite direction after haloperidol: injected aripiprazole (1 mg/kg) increased active-neuron counts. These findings show dependence on model and prior treatment; population activity is distinct from firing rate. [3]

Gentle-touch behavior in wild-type and receptor-deficient worms

Animal study · Live Caenorhabditis elegans: N2 and dopamine/serotonin receptor-deficient strains, assessed at L4. [2]

At 300 µM, aripiprazole reduced gentle-touch responses in N2 worms. No significant drug-associated change was detected in dop-1 or dop-2 single mutants, whereas a change remained in dop-3. These behavioral comparisons suggest receptor involvement but do not measure receptor binding affinity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Within-N2 comparison with vs without 300 µM aripiprazoleOne-way ANOVA F = 109.85; P = .001; n = 70 per condition[2]
Within-genotype comparisons with vs without aripiprazoleOne-way ANOVA dop-1: P = .314 (n = 70 per condition); dop-2: P = .321 (n = 70 per condition); dop-3: P = .001 (n = 70 per condition)[2]

Conditions shared by the study groups

Route
Exposure on drug-containing NGM agar plates.
Frequency
Grown on drug-containing medium from eggs or synchronized L1 larvae to late L4; no discrete dosing frequency reported.
Treatment course
Eggs or synchronized L1 larvae to late L4; elapsed hours not specified.
Vehicle
1% DMSO in NGM agar medium.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
N2: aripiprazole vs same-genotype vehicle
300 µM nominal concentration in NGM agar medium; not an internal dose.
N2 on NGM agar with 1% DMSO and no antipsychotic; n = 70 worms per condition.Reduced gentle-touch response; F = 109.85; P = .001. n = 70 worms per condition; within-genotype one-way ANOVA.[2]
dop-1: aripiprazole vs same-genotype vehicle
300 µM nominal concentration in NGM agar medium; not an internal dose.
dop-1 on NGM agar with 1% DMSO and no antipsychotic; n = 70 worms per condition.No significant drug-associated difference; P = .314. n = 70 worms per condition; within-genotype one-way ANOVA.[2]
dop-2: aripiprazole vs same-genotype vehicle
300 µM nominal concentration in NGM agar medium; not an internal dose.
dop-2 on NGM agar with 1% DMSO and no antipsychotic; n = 70 worms per condition.No significant drug-associated difference; P = .321. n = 70 worms per condition; within-genotype one-way ANOVA.[2]
dop-3: aripiprazole vs same-genotype vehicle
300 µM nominal concentration in NGM agar medium; not an internal dose.
dop-3 on NGM agar with 1% DMSO and no antipsychotic; n = 70 worms per condition.Significant drug-associated difference remained; P = .001. n = 70 worms per condition; within-genotype one-way ANOVA.[2]
dop-1; dop-2: aripiprazole vs same-genotype vehicle
300 µM nominal concentration in NGM agar medium; not an internal dose.
dop-1; dop-2 on NGM agar with 1% DMSO and no antipsychotic; n = 30 worms per condition.No significant drug-associated difference; P = .146. n = 30 worms per condition; within-genotype one-way ANOVA.[2]
dop-1; dop-3: aripiprazole vs same-genotype vehicle
300 µM nominal concentration in NGM agar medium; not an internal dose.
dop-1; dop-3 on NGM agar with 1% DMSO and no antipsychotic; n = 30 worms per condition.No significant drug-associated difference; P = .696. n = 30 worms per condition; within-genotype one-way ANOVA.[2]
dop-2; dop-3: aripiprazole vs same-genotype vehicle
300 µM nominal concentration in NGM agar medium; not an internal dose.
dop-2; dop-3 on NGM agar with 1% DMSO and no antipsychotic; n = 30 worms per condition.No significant drug-associated difference; P = .555. n = 30 worms per condition; within-genotype one-way ANOVA.[2]
dop-1; dop-2; dop-3: aripiprazole vs same-genotype vehicle
300 µM nominal concentration in NGM agar medium; not an internal dose.
dop-1; dop-2; dop-3 on NGM agar with 1% DMSO and no antipsychotic; n = 30 worms per condition.No significant drug-associated difference; P = .503. n = 30 worms per condition; within-genotype one-way ANOVA.[2]
N2: aripiprazole vs same-genotype vehicle
Model: Live C. elegans N2; assessed at late L4.
Reported limits: No measured internal exposure, exact elapsed exposure hours, SKU/lot or salt/hydrate characterization. Table 4 n counts worms, not independent experiments.
dop-1: aripiprazole vs same-genotype vehicle
Model: Live C. elegans dop-1; assessed at late L4.
Reported limits: No measured internal exposure, exact elapsed exposure hours, SKU/lot or salt/hydrate characterization. Table 4 n counts worms, not independent experiments.
dop-2: aripiprazole vs same-genotype vehicle
Model: Live C. elegans dop-2; assessed at late L4.
Reported limits: No measured internal exposure, exact elapsed exposure hours, SKU/lot or salt/hydrate characterization. Table 4 n counts worms, not independent experiments.
dop-3: aripiprazole vs same-genotype vehicle
Model: Live C. elegans dop-3; assessed at late L4.
Reported limits: No measured internal exposure, exact elapsed exposure hours, SKU/lot or salt/hydrate characterization. Table 4 n counts worms, not independent experiments.
dop-1; dop-2: aripiprazole vs same-genotype vehicle
Model: Live C. elegans dop-1; dop-2; assessed at late L4.
Reported limits: No measured internal exposure, exact elapsed exposure hours, SKU/lot or salt/hydrate characterization. Table 4 n counts worms, not independent experiments.
dop-1; dop-3: aripiprazole vs same-genotype vehicle
Model: Live C. elegans dop-1; dop-3; assessed at late L4.
Reported limits: No measured internal exposure, exact elapsed exposure hours, SKU/lot or salt/hydrate characterization. Table 4 n counts worms, not independent experiments.
dop-2; dop-3: aripiprazole vs same-genotype vehicle
Model: Live C. elegans dop-2; dop-3; assessed at late L4.
Reported limits: No measured internal exposure, exact elapsed exposure hours, SKU/lot or salt/hydrate characterization. Table 4 n counts worms, not independent experiments.
dop-1; dop-2; dop-3: aripiprazole vs same-genotype vehicle
Model: Live C. elegans dop-1; dop-2; dop-3; assessed at late L4.
Reported limits: No measured internal exposure, exact elapsed exposure hours, SKU/lot or salt/hydrate characterization. Table 4 n counts worms, not independent experiments.
Methods and source locations

Compound reported in the paper: Aripiprazole; Compound label in the paper: Ari

Evidence applies to the reported research material; no salt conversion, current Adooq lot equivalence, or clinical efficacy inferred.

Materials and Methods: Table 1, drug assays, gentle touch assay and statistical analysis; Results genotype-comparison subsection; Table 4

Within-N2 comparison with vs without 300 µM aripiprazole: At least three independent experiments with at least ten worms per condition; same-strain vehicle controls. — Table 4, N2 row and footnotes; Behavioral assays

Within-genotype comparisons with vs without aripiprazole: Genotype-specific vehicle comparisons, not direct affinity measurements. Double/triple dopamine receptor mutants also lacked significant effects (Table 4). — Table 4, dop-1, dop-2, dop-3 and double/triple-mutant rows

N2: aripiprazole vs same-genotype vehicle · XML table-wrap[@id="table4-1179069518798628"], N2 row and footnotes; table1-1179069518798628; sections section5, section6, section7 and section12 (each suffixed -1179069518798628).

dop-1: aripiprazole vs same-genotype vehicle · XML table-wrap[@id="table4-1179069518798628"], dop-1 row and footnotes; table1-1179069518798628; sections section5, section6, section7 and section12 (each suffixed -1179069518798628).

dop-2: aripiprazole vs same-genotype vehicle · XML table-wrap[@id="table4-1179069518798628"], dop-2 row and footnotes; table1-1179069518798628; sections section5, section6, section7 and section12 (each suffixed -1179069518798628).

dop-3: aripiprazole vs same-genotype vehicle · XML table-wrap[@id="table4-1179069518798628"], dop-3 row and footnotes; table1-1179069518798628; sections section5, section6, section7 and section12 (each suffixed -1179069518798628).

dop-1; dop-2: aripiprazole vs same-genotype vehicle · XML table-wrap[@id="table4-1179069518798628"], dop-1; dop-2 row and footnotes; table1-1179069518798628; sections section5, section6, section7 and section12 (each suffixed -1179069518798628).

dop-1; dop-3: aripiprazole vs same-genotype vehicle · XML table-wrap[@id="table4-1179069518798628"], dop-1; dop-3 row and footnotes; table1-1179069518798628; sections section5, section6, section7 and section12 (each suffixed -1179069518798628).

dop-2; dop-3: aripiprazole vs same-genotype vehicle · XML table-wrap[@id="table4-1179069518798628"], dop-2; dop-3 row and footnotes; table1-1179069518798628; sections section5, section6, section7 and section12 (each suffixed -1179069518798628).

dop-1; dop-2; dop-3: aripiprazole vs same-genotype vehicle · XML table-wrap[@id="table4-1179069518798628"], dop-1; dop-2; dop-3 row and footnotes; table1-1179069518798628; sections section5, section6, section7 and section12 (each suffixed -1179069518798628).

State-dependent acute effects on dopamine-neuron population activity

Animal study · Male Sprague-Dawley offspring, 3–6 months old (≥300 g), prenatal MAM model and prenatal saline (SAL) controls; recordings under chloral hydrate anesthesia. [3]

A single oral aripiprazole dose reduced the number of spontaneously active VTA dopamine neurons in MAM rats at 3 and 10 mg/kg. SAL rats did not show a significant population-activity reduction. Neither group showed a significant treatment-related change in mean firing rate or burst activity in the acute experiment.

Conditions shared by the study groups

Route
Oral, via palatable wafer
Frequency
Single administration
Treatment course
Single dose; recordings start at 2 h.
Vehicle
Wafer with liquid sugar.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MAM: acute oral aripiprazole
3 mg/kg or 10 mg/kg
MAM vehicle: n = 6 rats, 63 neurons; 1.7 ± 0.1 cells/track.Population activity reduced vs MAM vehicle: 3 mg/kg, n = 6 rats / 37 neurons, P = 0.007; 10 mg/kg, n = 10 rats / 63 neurons, P = 0.001 (Tukey post hoc). No significant firing-rate or bursting change.[3]
SAL: acute oral aripiprazole
3 mg/kg or 10 mg/kg
SAL vehicle: n = 8 rats, 61 neurons; 1.1 ± 0.1 cells/track.No significant population-activity reduction: 3 mg/kg, n = 6 rats / 41 neurons; 10 mg/kg, n = 8 rats / 66 neurons. No significant firing-rate or bursting change.[3]
MAM: acute oral aripiprazole
Model: Male Sprague-Dawley offspring, 3–6 months old (≥300 g), prenatal MAM model and prenatal saline (SAL) controls; recordings under chloral hydrate anesthesia.
SAL: acute oral aripiprazole
Model: Male Sprague-Dawley offspring, 3–6 months old (≥300 g), prenatal MAM model and prenatal saline (SAL) controls; recordings under chloral hydrate anesthesia.
Methods and source locations

Compound reported in the paper: Aripiprazole; Compound label in the paper: ARI

Evidence applies to the reported research material; no salt conversion, current Adooq lot equivalence, or clinical efficacy inferred.

Methods: Subjects, Acute and repeated aripiprazole administration, Electrophysiological recordings, Analysis; Results acute oral subsection; Figure 1A–C

MAM: acute oral aripiprazole · Methods: Subjects, Acute and repeated aripiprazole administration, Electrophysiological recordings, Analysis; Results acute oral subsection; Figure 1A–C

SAL: acute oral aripiprazole · Methods: Subjects, Acute and repeated aripiprazole administration, Electrophysiological recordings, Analysis; Results acute oral subsection; Figure 1A–C

Reversal of haloperidol-induced reduction in active dopamine neurons

Animal study · Male MAM-model Sprague-Dawley rats after acute haloperidol; within-animal VTA recordings under chloral hydrate anesthesia. [3]

In haloperidol-pretreated MAM rats, acute aripiprazole increased spontaneously active dopamine-neuron counts, consistent with reversal of depolarization block. Saline challenge did not significantly change the count. Mean firing rate and bursting were not significantly changed between groups.

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single administration
Vehicle
Saline.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Haloperidol followed by aripiprazole
Aripiprazole 1 mg/kg
Within-animal pre-aripiprazole recordings, plus separate haloperidol→saline group.n = 8 rats; population activity increased from 0.6 ± 0.1 to 1.4 ± 0.1 cells/track; paired t(7) = −4.031, P = 0.005. No significant group difference in firing rate or bursting.[3]
Haloperidol followed by saline control
Saline 1 ml/kg
Within-animal pre-saline recordings.n = 7 rats; population activity 0.8 ± 0.2 before and 0.7 ± 0.2 cells/track after saline; no significant change.[3]
Haloperidol followed by aripiprazole
Model: MAM rats pretreated with haloperidol 0.6 mg/kg i.p.
Treatment course: One challenge; post-challenge tracks start at 10 min.
Haloperidol followed by saline control
Model: MAM rats pretreated with haloperidol 0.6 mg/kg i.p.
Treatment course: One challenge; post-challenge recordings.
Methods and source locations

Compound reported in the paper: Aripiprazole; Compound label in the paper: ARI

Evidence applies to the reported research material; no salt conversion, current Adooq lot equivalence, or clinical efficacy inferred.

Methods: Acute haloperidol administration, Electrophysiological recordings and Analysis; Results final subsection; Figure 4B–F

Haloperidol followed by aripiprazole · Methods: Acute haloperidol administration, Electrophysiological recordings and Analysis; Results final subsection; Figure 4B–F

Haloperidol followed by saline control · Methods: Acute haloperidol administration, Electrophysiological recordings and Analysis; Results final subsection; Figure 4B–F

Specifications

Manufacturer Adooq Bioscience
Actions Partial Agonist
CAS Number 129722-12-9
Applications 5-HT1A receptor agonist
Formula C23H27Cl2N3O2
Molecular Weight 448.39
Synonyms Abilify
SMILES
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 79 mg/mL (176.18 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Brust TF, Hayes MP, Roman DL, et al. New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling Biochemical pharmacology (2015). PMID: 25449598 DOI: 10.1016/j.bcp.2014.10.014 Source material
  2. [2] Osuna-Luque J, Rodríguez-Ramos Á, Gámez-Del-Estal MDM, et al. Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole Journal of experimental neuroscience (2018). PMID: 30245571 DOI: 10.1177/1179069518798628 Source material
  3. [3] Sonnenschein SF, Gill KM, Grace AA. State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2019). PMID: 30267014 DOI: 10.1038/s41386-018-0219-1 Source material

Publications

1 publication citing this product

  1. Jaime Osuna-Luque, .et al. , J Exp Neurosci, 2018, 12: 1179069518798628 PMID: 30245571

Added to your cart

View Cart Checkout
Loading...